Physician profile
Rafael Crespo
NPI 1104866235
$1,345.60
in general payments reported to CMS, 2019-2025
22 companies · $89.84 in 2025
The $89.84 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $63.50 · 2021: $99.71 · 2022: $167 · 2023: $418 · 2024: $152 · 2025: $89.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $660.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $368.26 | 2019-2024 | Trelegy Ellipta |
| Abbvie INC. | $170.84 | 2022-2024 | Vraylar |
| Inari Medical, INC. | $161.49 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Janssen Pharmaceuticals, INC | $66.15 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.05 | 2019-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $61.74 | 2019 | |
| Allergan, INC. | $56.53 | 2019 | |
| Exact Sciences Corporation | $55.52 | 2025 | The Cologuard Plus Collection Kit |
| Pfizer INC. | $51.46 | 2019 | |
| Sanofi-Aventis U.S. LLC | $44.12 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $35.73 | 2019 | |
| Abbott Laboratories | $24.85 | 2022 | |
| Novo Nordisk INC | $21.52 | 2019 | |
| Amgen INC. | $21.50 | 2024 | Repatha, Otezla |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.80 | 2024 | Lifevest |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $20.25 | 2019 | |
| Idorsia Pharmaceuticals US INC | $19.51 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.15 | 2020 | |
| Gilead Sciences, INC. | $15.84 | 2024 | |
| Amarin Pharma, INC. | $15.71 | 2021 | |
| Esperion Therapeutics, INC. | $14.38 | 2021 | |
| Cipher Pharmaceuticals US LLC | $14.20 | 2025 | Spinosad, Natroba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Crespo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.